

6. (Amended) An antibody according to Claim 1, wherein the antibody is a monoclonal antibody.
7. (Amended) An antibody according to Claim 1, wherein the antibody is a human antibody.
9. (Amended) An antibody according to Claim 1, wherein the antibody is a humanized antibody.
10. (Amended) An antibody according to Claim 1, wherein the antibody is a recombinant antibody.
37. (Amended) A composition comprising an antibody which binds to a mammalian CC-chemokine receptor 2, wherein the antibody inhibits binding of a ligand to the receptor, and an optional physiologically acceptable vehicle.
38. (Amended) An antibody which binds to a mammalian CC-chemokine receptor 2, wherein the antibody inhibits binding of a ligand to the receptor with an  $IC_{50}$  of less than about 1.0  $\mu\text{g/ml}$ .
39. (Amended) An antibody according to Claim 38 wherein the  $IC_{50}$  is less than about 0.05  $\mu\text{g/ml}$ .
40. (Amended) An antibody which binds to a mammalian CC-chemokine receptor 2, wherein the antibody inhibits binding of a ligand to the receptor, and wherein the antibody binds the receptor with an affinity of at least about  $0.1 \times 10^{-9}$  M.
41. (Amended) An antibody according to Claim 40, wherein the affinity is at least about  $1 \times 10^{-9}$  M.

42. (Amended) An antibody according to Claim 40, wherein the affinity is at least about  $3 \times 10^{-9}$  M.
43. (Amended) A method of treating a CC-chemokine receptor 2-mediated disorder in a patient, comprising administering to the patient an effective amount of an antibody which binds to a mammalian CC-chemokine receptor 2, wherein the antibody inhibits binding of a ligand to the receptor.

Amendments to the claims are indicated in the attached "Marked Up Version of Amendments" (pages i - v).

Please add new Claims 44-57 as follows:

44. (New) An antigen-binding fragment of an antibody which binds to a mammalian CC-chemokine receptor 2 and inhibits binding of a ligand to the receptor, wherein the antigen-binding fragment inhibits binding of a ligand to the receptor.
45. (New) An antigen-binding fragment according to Claim 44, wherein the antigen-binding fragment inhibits one or more functions associated with binding of the ligand to the receptor.
46. (New) An antigen-binding fragment according to Claim 44, wherein the mammalian CC-chemokine receptor 2 is a human CC-chemokine receptor 2.
47. (New) An antigen-binding fragment according to Claim 44, wherein the ligand is a chemokine.
48. (New) An antigen-binding fragment according to Claim 47, wherein the chemokine is selected from the group consisting of MCP-1, MCP-2, MCP-3, MCP-4 and combinations thereof.

49. (New) An antigen-binding fragment according to Claim 44, wherein the antibody is a monoclonal antibody.
50. (New) An antigen-binding fragment according to Claim 44, wherein the antibody is a human antibody.
51. (New) An antigen-binding fragment according to Claim 44, wherein the antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')<sub>2</sub> fragment.
52. (New) An antigen-binding fragment according to Claim 44, wherein the antibody is a humanized antibody.
53. (New) An antigen-binding fragment according to Claim 44, wherein the antibody is a recombinant antibody.
54. (New) A composition comprising an antigen-binding fragment of an antibody which binds to a mammalian CC-chemokine receptor 2 and inhibits binding of a ligand to the receptor, wherein the antigen-binding fragment inhibits binding of a ligand to the receptor, and an optional physiologically acceptable vehicle.
55. (New) An antigen-binding fragment of an antibody which binds to a mammalian CC-chemokine receptor 2 and inhibits binding of a ligand to the receptor with an IC<sub>50</sub> of less than about 1.0 µg/ml, wherein the antigen-binding fragment inhibits binding of a ligand to the receptor with an IC<sub>50</sub> of less than about 1.0 µg/ml.
56. (New) An antigen-binding fragment of an antibody which binds to a mammalian CC-chemokine receptor 2 with an affinity of at least about 0.1 x 10<sup>-9</sup> M and inhibits binding of a ligand to the receptor, wherein the antigen-binding fragment binds to a mammalian

A13